November 2, 2017 / 6:32 AM / a year ago

Sanofi refines expectations on drop in sales at diabetes arm

PARIS, Nov 2 (Reuters) - Sanofi confirmed its 2017 outlook after it posted slightly lower-than-expected third-quarter results, and gave a more precise range on expectations of a sales decline at its embattled diabetes business.

The French drugmaker said currency-adjusted sales at its diabetes franchise would likely shrink by 6-8 percent per year between 2015 and 2018.

It had previously seen a 4-8 percent drop due to persistent pricing pressure in the United States, but added it had now better visibility on the sales expectations of this unit.

Sanofi’s third-quarter business net income fell 1.1 percent at constant exchange rates to 2.141 billion euros ($2.5 billion). Total sales rose 4.7 percent to 9.05 billion euros.

Analysts polled by Reuters were expecting business net profit of 2.148 billion euros and net sales of 9.33 billion.

$1 = 0.8581 euros Reporting by Matthias Blamont; Editing by Sudip Kar-Gupta

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below